← Russell 3000 cross-section

STXS Stereotaxis, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$150m
Revenue TTM
$30m
Net income TTM
$-22m
Free cash flow
Composite score
Sector rank
#2963

Valuation

P / E
EV / EBITDA
EV / sales
4.6
FCF yield
Earnings yield vs 10-yr
-19.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-74.2%
EBITDA margin
-70.4%
ROE
-182.3%
ROIC
-1,298.8%
Revenue growth
-5.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We source certain subassemblies from Mexico, all of which qualify under USMCA; therefore, these items were not subject to the increased tariff, and the effect on our cost of revenue for the six months ended June 30, 2026, was immaterial. During the six months ended June 30, 2026, tariffs and other trade measures recognized in total cost of revenue were not material. Customer deposits primarily relate to future system sales but can also include deposits on disposable sales. Revenue decreased from $8.8 million for the three months ended June 30, 2025, to $7.7 million for the three months ended June 30, 2026, a decrease of 13%. …Stereotaxis, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →